Acrux Limited · ASX:ACR
Acrux — FY2018 Earnings Presentation
16 slides from Acrux's earnings presentation, Aug 16, 2018
Slide 1: FY18 Annual Results Presentation
For personal use only Acrux (ASX: ACR) FY18 Annual Results Presentation 17 August 2018 1
Slide 2: Forward looking statements
Forward looking statements For personal use only This presentation includes forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Acrux to be mate
Slide 3: Agenda
Agenda For personal use only FY18 Achievements Full Year P&L and Cashflow FY19 Objectives 3
Slide 4: FY18 operational highlights
FY18 operational highlights For personal use only EXCELLENT R&D PROGRESS ON-SCHEDULE FDA APPLICATION HEALTHY CASH BALANCE ▪ Continued solid progress on our ▪ Acrux submitted its application to ▪ Net cash spend on operating portfolio of generic topical drugs market a generic version of activities of
Slide 5: Strategy recap: Topical generic portfolio
Strategy recap: Topical generic portfolio For personal use only SIGNIFICANT MARKET OPPORTUNITY (US$18bn) ADVANTAGES OF GENERIC STRATEGY US$400+ bn1 US$18bn2 • Fast development and low cost 12% Other • $3-4m to develop each generic 4% Topical 47% Generic 34% Injectable Acrux chose to target • Lower r
Slide 6: Generic pipeline continues to progress
Generic pipeline continues to progress For personal use only Formulation Process Bioequiv. / Regulatory Approved / Development Development clinical1 Submission Launched Branded Project # Target area Development phase equivalent 1 Jublia® Toenail Infection ✓ 13 products in Generic Topical portfolio,
Slide 7: Significant variation within topical generic pipeline
Significant variation within topical generic pipeline For personal use only Numerous therapeutic areas A range of dosage forms Antifungals Anti-rheumatics Ointments Lotions Acne Analgesics Creams Pastes Hormones Anti-inflammatories Solutions Sprays Antivirals … Gels … No shortage of high value topic
Slide 8: Market value of drugs in pipeline >US$1.4bn
Market value of drugs in pipeline >US$1.4bn For personal use only ACRUX GENERIC PIPELINE ADDRESSABLE MARKET VALUE1, 2 Acrux is targeting a large and growing 1,500 addressable market 1,429 ✓ Addressable market of +US$1.4 billion* 139 41 159 Fewer generic products on the market 1,057 28 creates favour
Slide 9: First-to-file Generic of Jublia
First-to-file Generic of Jublia® For personal use only KEY HIGHLIGHTS ▪ Acrux has submitted an ANDA to the FDA for a generic version of Jublia® and this has been accepted for review ▪ Acrux eligible for 180 days of generic market exclusivity on final approval ▪ Jublia® US sales exceed $280 million p
Slide 10: Lenzetto update: Consistent royalty growth
Lenzetto® update: Consistent royalty growth For personal use only Lenzetto® overview Effective partnering Growing royalty revenues ✓ Product has been licensed to Gedeon Richter in Europe, who own the Lenzetto® Trademark ✓ Rollout of Lenzetto® commenced in Q1 2016 and has since successfully launched
Slide 11: Agenda
Agenda For personal use only FY18 Achievements Full Year P&L and Cashflow FY19 Objectives 11
Slide 12: Full year Profit and Loss
Full year Profit and Loss Full Year Ending For personal use only 2018 2017 $'000 $'000 % • Royalty revenue decreased 88.5% to $2.7m reflecting a decline in Axiron® global sales by our partner Eli Lilly and Company due to generic Royalty revenue 2,687 23,321 (88.5%) competition and the termination of
Slide 13: Full year Cashflow
Full year Cashflow For personal use only Full Year Ending 2018 2017 $'000 $'000 % • Cash received from product agreements was $7.9m, down 63.9% on prior financial year due to lower Axiron royalty receipts Cash flow from operating activities • Payments to suppliers and employees was $12.7m up 18.4% d
Slide 14: Agenda
Agenda For personal use only FY18 Achievements Full Year P&L and Cashflow FY19 Objectives 14
Slide 15: Outlook and objectives
Outlook and objectives For personal use only FY19 CY19 6 Technical Additional new First generic 2 dossiers Transfers products revenues Submit 2 additional dossiers Scale up 6 projects from to the FDA for review Acrux laboratory to Contract Add additional products to Generate first revenues Manufactu
Slide 16: FY18 Annual Results Presentation
For personal use only Acrux (ASX: ACR) FY18 Annual Results Presentation 17 August 2018